Apaziquone clinical trials
Also written EOquin and EO9.
How each study uses apaziquone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Spectrum Pharmaceuticals, Inc (7) · Handok Inc. (1) · Nippon Kayaku Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses apaziquone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT02563561Written as ApaziquoneHow we know
- A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT03224182Written as QapzolaHow we know
- Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)CompletedPhase 3Spectrum Pharmaceuticals, IncNCT00461591Written as ApaziquoneHow we know
- Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01469221Written as ApaziquoneHow we know
- Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)CompletedPhase 3Spectrum Pharmaceuticals, IncNCT00598806Written as ApaziquoneHow we know
- Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)TerminatedPhase 2/3Nippon Kayaku Co., Ltd.NCT01475266Written as EO9 (Apaziquone)How we know
- Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder CancerTerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01410565Written as ApaziquoneHow we know
- Phase II Trial of EOquin in High-risk Superficial Bladder CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00141531Written as ApaziquoneHow we know
- Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)CompletedPhase 1Handok Inc.NCT01373398Written as EO9(Apaziquone)How we know
Codes
What other systems call apaziquone · ClinicalTrials.gg INT003454
- MeSH (NLM) C060817apaziquoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) H464ZO600OAPAZIQUONEConfirmed FDA, NLM, Wikidata
- Wikidata Q4779259apaziquoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1087ApaziquoneOne source FDA
- DrugBank DB12593One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C060817 | apaziquone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | H464ZO600O | APAZIQUONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4779259 | apaziquone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1087 | Apaziquone | One source FDA |
| DrugBank | DB12593 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.